BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 22336203)

  • 21. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
    Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
    Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma.
    Chen R; Zhang M; Liu W; Chen H; Cai T; Xiong H; Sheng X; Liu S; Peng J; Wang F; Chen H; Lin W; Xu X; Zheng W; Jiang Q
    Cell Death Dis; 2018 Dec; 10(1):4. PubMed ID: 30584245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
    Lou HY; Lin kQ; Ye DF; Xie X; Yu X
    Ai Zheng; 2005 Jun; 24(6):748-50. PubMed ID: 15946494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
    Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
    Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
    Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
    Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.
    Bogusiewicz M; Semczuk A; Gogacz M; Skomra D; Jakowicki JA; Rechberger T
    Cancer Lett; 2006 Jul; 238(1):61-8. PubMed ID: 16085355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma.
    Gao Q; Ye F; Xia X; Xing H; Lu Y; Zhou J; Ma D
    J Huazhong Univ Sci Technolog Med Sci; 2009 Feb; 29(1):59-63. PubMed ID: 19224164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation.
    van Gent MD; Nicolae-Cristea AR; de Kroon CD; Osse EM; Kagie MJ; Trimbos JB; Hazelbag HM; Smit VT; Bosse T
    Int J Gynecol Cancer; 2016 Mar; 26(3):483-90. PubMed ID: 26825822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
    Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
    Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
    Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.